A na-eji ọgwụ ọjọọ eme ihe na ọgwụgwọ HIV nke nwere ike ịba ụba plasma nke ụfọdụ ndị na- egbochi nje nje (ARV) mgbe a na-eji ya agwọ ọrịa. Ndị a maara nke ọma dị ka ndị "boosters," ọgwụ ndị ahụ na-eme ka ndị dọkịta belata usoro ọgwụgwọ na ugboro ole ARV na-eje ozi ma na-ebelata ikike maka mmetụta ndị metụtara ọgwụ ọjọọ.
Ndị na-akwado nje HIV, ndị a makwaara dị ka ndị na-eme ka ọgwụcokinetic enhancers, ghara inwe mgbagwoju anya na vitamin ma ọ bụ ihe mgbakwunye ahịa dị ka "immun boosters," nke na-enweghị ihe a maara maka ma ọ bụ igbochi ma ọ bụ ịlụso nje HIV ọgụ.
Okwu Mmalite nke Boosters HIV
Mgbe mbụ a chọpụtara na ndị na-egbochi nje HIV bụ ndị na-egbochi nje HIV n'ime afọ ndị 1990, otu n'ime ihe ịma aka ndị siri ike ndị na-eme nnyocha bụ ọsọ ọsọ nke ọgwụ ndị ahụ na-emeju na imeju na kpochapụ ọbara. N'ihi ya, PI chọrọ ugboro abụọ - na-edozi ugboro atọ kwa ụbọchị. Ọ bụghị naanị na akwa dosages na-amụba ihe ize ndụ nke ọgwụ ọjọọ, ibu nnukwu mpi ibu arọ na-agbaso ihe niile siri ike (na mmepe nke iguzogide ọ bụla ka yikarịrị).
N'afọ 1996, a kwadoro ọgwụ Norvir (ritonavir) maka ọgwụ nje US Food and Drug Administration (FDA) na HIV. Ọ bụ ezie na a maara ọgwụ ahụ na ọ nwere ihe antiviral, ọ chọpụtara n'oge na-adịghị anya na, ọbụna na obere doses, ọ nwere ike igbochi enzyme ahụ (CYP3A4) dị mkpa iji mepụta PI.
Ihe nchoputa ahu metutara uzo eji edozi uzo. Taa, a naghị eji Norvir mee ihe iji mee ihe ọ bụla, ma ọ bụghị iji mee ka ọrụ PI dị iche iche dị irè, ebe ọ na-ebelata nsogbu ndị metụtara ọrịa.
Ọgwụ ahụ bụkwa otu akụkụ nke ngwakọta ọgwụ dị iche iche PI, Kaletra (lopinavir + ritonavir).
(Biko rịba ama na - Norvir nwere ike igbochi ihe nrịba plasma nke ọgwụ ndị ọzọ ị nwere ike ịnweta, mgbe ụfọdụ ọ na-akpata oké mkparịta ụka dị njọ. Biko gwa dọkịta gị banyere ọgwụ ọ bụla ị na-eji ma ọ bụ Norvir ma ọ bụ Kaletra.
Ọdịnihu nke nje HIV
N'ime afọ ndị na-adịbeghị anya, e lebawo anya na mmepe nke ndị ọzọ na-ebuli nje HIV. A na-ahụ anya na ndị ọrụ yiri nke ahụ nwere ike ọ bụghị naanị na-agbasawanye nrụpụta nke PI, mana ha na-eme otu maka nje ndị ọzọ nke ARV-nke nwere ike ịdị n'otu, otu ugboro kwa ụbọchị, ma na-ahapụ "mgbaghara" ka ukwuu ma ọ bụ ọdịiche nke ọgwụgwọ eme.
N'afọ 2012, afọ iri isii na isii mgbe iwebata Norvir, FDA kwadoro ọgwụ nke abụọ. A na-egosi na a na-emepụta ọgwụ ndị na-ejikọta ọnụ (Strubber) (elvitegravir + cobicistat + tenofovir + emtricitabine) , iji mechie ma ọ bụ enzyme CYP3A4 na ọgwụ ndị na-agwọ ọrịa nke a maara iji gbochie ọgwụ absorption.
Ọ bụ ezie na o nweghị ihe ọ bụla na-eme ka ọ bụrụ nke onwe ya, Tybost nwere ike ịmalite ịrụ ọrụ elvitegravir, onye na-ebute nje HIV, ma nweta ihe yiri ya na PI Reyataz (atazanavir) na Prezista (darunavir) na anacleotide analogue Viread (tenofovir).
Ná mmalite nke afọ 2015, FDA kwadoro ọgwụ abụọ, ọgwụ ndị na-emezi ọgwụ na-emetụta Tybost, gụnyere Evotaz (atazanvir + cobicistat) na Prezcobix (darunavir + cobicistat) .
A na-enyocha ndị ọzọ na-akwado boosters, tinyere onye edemede CYP3A4 nke Sequoia Pharmaceuticals mepụtara.
Isi mmalite:
National Institute of Allergies and Diseases (NIAID). "Ndị ọhụrụ na-egbochi protease ọhụrụ kwadoro FDA. Nchịkwa nri na ọgwụ ọjọọ. " NAIAID AIDS Agenda. Bethesda, Maryland; March 1996; 4-5.
Nchịkwa nri na ọgwụgwọ US (FDA). "FDA kwadoro ọgwụ mgbochi ohuru maka ọgwụgwọ HIV maka ụfọdụ ọrịa." Silver Spring, Maryland; ntinye mgbasa ozi nke August 27, 2012.
Gallant, J .; Koenig, E .; Andrade-Villanueva, J .; et al. "Njikọ ọnụ na Ritonavir dịka onye na-enye ọgwụ na Atazanavir Plus Emtricitabine / Tenofovir Disoproxil Fumarate na Ọgwụgwọ - Ọrịa HIV Ụdị nke 1-Ndị Ọrịa Na-arịa: Izu 48 Ihe." Journal of Diseases Diseases. July 1, 2013, 208 (1): 32-39 .
Bristol-Myers Squibb. "Evotaz (Atazanvir + cobicistat) - NKWUKWỤKWU NDỊ ỌZỌ." New York, New York.
Bristol-Myers Squibb. "PREZCOBIX - NKWUKWU NDỊ NA-EKWU NDỊ." New York, New York.